For decades, ADVANZ PHARMA has been committed to providing patients with a wide range of high quality and trusted, innovative, originator, and generic therapies.
Leveraging generations of knowledge and expertise, ADVANZ PHARMA is proud to have invested in a portfolio of biosimilar medications, to be launched across multiple therapy areas with significant unmet needs. We now bring the same dedication that has defined our work in innovative, originator, and generic treatments to biosimilar drugs, offering healthcare providers more essential medicines to improve patient care.
This page will help you understand ADVANZ PHARMA's growing commitment to biosimilar pharmaceuticals and provide you with additional biosimilar resources to learn more:
Biologics are advanced, complex biological medicines derived from living organisms that have transformed patient care across numerous conditions. Unlike conventional drugs, their intricate molecular structures demand innovative production techniques.
Biosimilar pharmaceuticals are developed as highly similar versions of these established innovative biologics, offering a valuable alternative by providing a more affordable treatment option. Biosimilar drugs are designed to offer the same clinical benefits without meaningful differences in safety, purity, or efficacy. Undergoing comprehensive analytical assessments, clinical evaluations, and rigorous regulatory approval processes, biosimilar medications ensure that every patient receives dependable treatment backed by the highest standards of quality and performance.
By potentially reducing treatment costs, biosimilar medications can help optimize healthcare budgets, allowing for better resource allocation and reinvestment in further innovation and improving patient care. This approach supports broader access to essential therapies and contributes to the overall sustainability of healthcare systems.
For more information on biosimilars meaning and other details, access our educational resources here :
To ensure greater access to medicines for patients, ADVANZ PHARMA has actively sought the best biosimilar CDMOs (Contract Development and Manufacturing Organisations) partnerships to apply its scientific and commercial-led expertise in the field of quality assured, affordable biological medicines.
Our product portfolio boasts over 180 quality-assured medicines, distributed across more than 100 countries. Every year, our medicines reach over 262 million patients, offering prescribers dependable, accessible, and reliable treatment options to meet diverse healthcare needs. As the biosimilars market continues to grow, ADVANZ PHARMA remains committed to expanding market access for biosimilars through high-quality, affordable solutions.
Our experience makes us a trusted partner. With our proven track record navigating the complexities of affordability, access, and supply that challenge stakeholders in the European healthcare system, our biosimilar strategy ensures us to be uniquely placed to provide patients with high quality biosimilar treatment options.
Patients need more options, today and tomorrow. At ADVANZ PHARMA, we are rapidly building a long-term and diverse biosimilar portfolio across multiple therapeutic areas, with an ever-expanding pipeline to improve patient care at reduced costs, supporting EU healthcare system investment in innovative medicines.
Patients deserve continued and reliable access to treatments when they need them most. That's why the majority of ADVANZ PHARMA's biosimilar products are manufactured in Europe - leveraging local production and supply chains to ensure continued access.
We are working to create a better future. In collaboration with our biosimilar manufacturers, we embed sustainable and responsible practices across our operations to minimise our environmental impact. We also recognise the broader impact of biosimilars - not only in reducing treatment costs, but also in supporting more sustainable healthcare systems.
We believe patients deserve the best care. At ADVANZ PHARMA, we are focused on tailored solutions that support biosimilar patient care offering a wide range of presentations, dosages, and delivery systems designed to meet patient needs. We also address important clinical considerations such as biosimilar interchangeability, supporting evidence-based decision-making for patient care.
We make therapy transitions seamless. At ADVANZ PHARMA, we partner with healthcare providers to support biosimilar switching, delivering the necessary resources and support programs to make therapy transitions straightforward, integrating biosimilars into everyday clinical practice.
Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/ and also report using the Yellow Card app. The app is available to download from the Apple App Store, or Google Play Store and you can use your Yellow Card website account details on the app to report. Adverse events should also be reported to ADVANZ PHARMA Medical Information via telephone on +44 (0) 208 588 9131 or via e-mail at medicalinformation@advanzpharma.com
